Pink SheetThe European Medicines Agency has recommended that Gilead Sciences’ Yeytuo (lenacapavir), for preventing HIV, and 13 other new drugs should be granted pan-EU marketing authorization, but it has advise
ScripViking Therapeutics is continuing to advance dual GLP-1/GIP receptor agonist VK2735 on two tracks for obesity, with a pair of Phase III trials of the weekly injectable formulation under way, while a P
ScripAstraZeneca intends to bring a self-administered complement C5 inhibitor to market for generalized myasthenia gravis (gMG) now that gefurulimab has delivered positive Phase III results. The product co
ScripThe new director of the US Food and Drug Administration’s Center for Drug Evaluation and Research, George Tidmarsh, brings plenty of pharmaceutical experience to the post, which could be a comfort to